Bullish Moving Averages
14
Bearish Moving Averages
2
Back Stocks profile
Stock analysis tool for investors
Performance
Today’s low
14.50Today’s High
15.0052W low
10.0052W High
27.50Open Price
15.00Prev. Close
12.0000Volume
3272.00Value
48916.40Fundamentals
Market Cap
15.00
Price to Earnings
-12.60
Price to Book Value
-1.10
Dividend Yield
0.00
PE to Growth
-0.40
Op Revenue TTM
5.64
Net Profit TTM
-1.19
Cash From Operating Activity
0.34
Return on Equity %
0.00
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
100
Week
100
Month
100
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
14.81
PIVOT
First Resistance
15.09
Second Resistance
15.24
Third Resistance
15.52
First Support
14.66
Second Support
14.38
Third Support
14.23
Relative Strength Index
82.37
Money Flow Index
86.65
MACD
0.45
MACD Signal
0.07
Average True Range
0.33
Average Directional Index
25.75
Rate of Change (21)
24.48
Rate of Change (125)
11.9
Commodity Channel Index
265
Williams %R
BETA
1 Month
-1.11
3 Month
0.05
1 Year
0.17
3 Year
0.09
PRICE CHANGE ANALYSIS
↑ 27.23%
1 Week
Low
High
12
14.95
↑ 24.58%
1 Month
Low
High
11.3
14.95
↑ 2.4%
3 Months
Low
High
10.7
14.95
↓ -5.56%
6 Months
Low
High
10.7
27.51
↑ 34.2%
1 Year
Low
High
10.05
27.51
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 1.52 | 0.65 | 2.56 | 0.95 | 1.23 | 3.17 | 3.03 | 0.95 | 0.83 | 1.52 | 2.20 | |
| Operating Expenses Qtr | 1.00 | 0.69 | 2.80 | 1.33 | 0.67 | 2.83 | 2.79 | 1.15 | 1.25 | 1.56 | 2.33 | |
| Operating Profit Qtr | 0.49 | -0.04 | -0.25 | -0.39 | 0.55 | 0.34 | 0.24 | -0.20 | -0.43 | -0.05 | -0.13 | |
| EBIDT Qtr Cr | 0.51 | -0.04 | -0.25 | -0.39 | 0.56 | 0.34 | 0.24 | -0.20 | -0.41 | -0.03 | -0.13 | |
| Depreciation Qtr | 0.14 | 0.14 | 0.14 | 0.14 | 0.18 | 0.15 | 0.15 | 0.15 | 0.66 | -0.32 | 0.16 | |
| Net Profit Qtr | 0.17 | -0.27 | -0.48 | -0.61 | -0.54 | -0.20 | -0.56 | -0.44 | -2.23 | -0.19 | -0.79 | |
| Basic EPS Qtr | 0.17 | -0.27 | -0.48 | -0.61 | -0.54 | -0.20 | -0.56 | -0.44 | -2.23 | -0.19 | -0.79 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 5.66 | 8.37 | 9.46 | 12.30 | 7.93 | |
| Operating Expenses Annual Cr | 5.82 | 7.44 | 9.51 | 14.00 | 10.00 | |
| Operating Profit Annual | -0.18 | 0.92 | -0.07 | -1.74 | -2.16 | |
| Operating Profit Margin Annual % | -3.26 | 11.02 | -0.76 | -14.18 | -27.18 | |
| Total Expenses Annual Cr | 6.76 | 9.57 | 11.65 | 16.30 | 11.61 | |
| EBIDT Annual Cr | -0.16 | 0.94 | -0.05 | -1.69 | -2.07 | |
| EBIDT Annual margin % | -2.76 | 11.19 | -0.49 | -13.75 | -26.11 | |
| Depreciation | 0.57 | 0.63 | 0.66 | 0.67 | 0.73 | |
| PAT Before ExtraOrdinary Items Annual Cr | -1.19 | -1.75 | -3.26 | -4.96 | -2.84 | |
| Net Profit Annual | -1.19 | -1.75 | -3.26 | -4.96 | -2.84 | |
| Basic EPS Annual | -1.19 | -1.75 | -3.26 | -4.96 | -2.84 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | -13.63 | -12.44 | -10.69 | -7.43 | -2.47 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 18.59 | 18.43 | 18.10 | 15.52 | 14.98 | |
| Total Current Liabilities Annual Cr | 9.19 | 7.70 | 6.78 | 11.69 | 8.04 | |
| Total Capital Plus Liabilities Annual Cr | 14.15 | 13.69 | 14.19 | 19.79 | 20.56 | |
| Fixed Assets Annual | 5.79 | 6.47 | 7.07 | 7.67 | 8.25 | |
| Total Non Current Assets Annual | 8.01 | 8.77 | 9.92 | 11.55 | 13.11 | |
| Total Current Assets Annual | 6.14 | 4.92 | 4.27 | 8.23 | 7.44 | |
| Total Assets Annual | 14.15 | 13.69 | 14.19 | 19.79 | 20.56 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 1.33 | 1.33 | 1.33 | 0.00 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 0.34 | 1.20 | -1.01 | 1.11 | -2.88 | |
| Cash from Investing Activity Annual | 0.10 | -0.02 | -0.09 | -0.06 | 0.00 | |
| Cash from Financing Annual Activity | -0.20 | -1.18 | 1.10 | -1.09 | 2.86 | |
| Net Cash Flow Annual | - | 0.00 | -0.00 | -0.04 | -0.02 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | -13.73 | -12.54 | -10.77 | -7.49 | -2.49 | |
| ROE Annual % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ROCE Annual % | -14.67 | 5.13 | -9.49 | -29.14 | -22.36 | |
| Total Debt to Total Equity Annual | -1.58 | -1.48 | -1.69 | -2.09 | -6.07 | |
| EBDIT Annual Margin % | -2.77 | 11.20 | -0.48 | -13.80 | -26.38 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| VIMAL D SHAH | 23.6 | 75061649 | 0 | 0 |
| NAVSARJAN INVESTMENT & TRADING PVT LTD | 10 | 75061650 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| FAB METALS PRIVATE LIMITED | 41.99 | 75061670 |
| LKP SECURITIES LIMITED | 1.5 | 75061671 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 29, 2024 | Audited Results | - |
| Feb 14, 2024 | Quarterly Results | - |
| Dec 29, 2023 | Others | Inter alia : 1. To Consider and approve Authorized Signatory for Bank Operations. 2. To Consider and recommend Mr. Vimal Shah as a Director of the Company subject to Members approval. |
| Nov 18, 2023 | A.G.M. | - |
| Nov 10, 2023 | Quarterly Results | - |
| Aug 10, 2023 | Quarterly Results | - |
| May 25, 2023 | Audited Results | - |
| Feb 13, 2023 | Quarterly Results | - |
| May 25, 2022 | Audited Results | - |
| Feb 12, 2022 | Quarterly Results | - |
| Nov 12, 2021 | Quarterly Results | - |
| Aug 14, 2021 | Quarterly Results | - |
| Jun 28, 2021 | Audited & Quarterly Results | - |
| Feb 13, 2021 | Quarterly Results | - |
| Nov 11, 2020 | Quarterly Results | - |
| Aug 24, 2020 | Quarterly Results | - |
| Jun 29, 2020 | Audited Results | - |
| Feb 06, 2020 | Quarterly Results | - |
| Oct 23, 2019 | Quarterly Results | - |
| Aug 05, 2019 | Quarterly Results | - |
| May 29, 2019 | Audited Results | - |
| Feb 09, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Aug 06, 2018 | Unaudited Financial Results | - |
| May 26, 2018 | Audited Results | - |
| Feb 02, 2018 | Quarterly Results | - |
| Nov 16, 2017 | Quarterly Results | - |
| Aug 14, 2017 | Quarterly Results | - |
| May 29, 2017 | Audited Results | - |
| Feb 03, 2017 | Quarterly Results | - |
| Nov 08, 2016 | Quarterly Results | - |
| May 22, 2016 | Audited Results | - |
| Feb 14, 2016 | Quarterly Results | Considered the Statement of Investor's Complaints and Redressal for Quarter ended as on December 31, 2015 under Reg. 13(3) of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015. |
| Aug 24, 2013 | Consolidation of share capital | To allot new equity shares of Rs. 10/- each after reduction and consolidation of share capital of the Company pursuant to BIFR order. |
| Aug 05, 2013 | Others | - |
| Sep 20, 2000 | Preferential Offer | Allotment of 1,80,00,000 equity shares of Rs. 10/- each at par to PHC Holding Group on Preferential Basis |
| Sep 04, 2000 | Accounts | - |
| Jul 31, 2000 | Quarterly Results | - |
| May 22, 2000 | Preferential/Private Placement | - |
| Apr 29, 2000 | Quarterly Results | - |
| Jan 31, 2000 | Quarterly Results | - |
| Jul 31, 1999 | Quarterly Results | - |
| Apr 30, 1999 | Quarterly Results | - |
| Nov 30, 1998 | Accounts | - |
| May 30, 1998 | Half Yearly Results | - |
| Dec 30, 1997 | Accounts | - |
| May 30, 1997 | Half Yearly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
03 Jul 2024
NORRIS MEDICINES LTD. - 524414 - Announcement under Regulation 30 (LODR)-Change in Management
The Company has appointed CS Priyanka Lohiya, Membership Number: A70191, as a Company Secretary, Compliance Officer and KMP of the Company.
29 Jun 2024
NORRIS MEDICINES LTD. - 524414 - Announcement under Regulation 30 (LODR)-Change in Management
As per attachment.
29 May 2024
NORRIS MEDICINES LTD. - 524414 - Audited Financial Results For The Quarter And Year Ended March 31 2024
approval of audited results for the quarter and year ended March 31 2024.
29 May 2024
NORRIS MEDICINES LTD. - 524414 - Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May, 2024 Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
1. Approval of Audited Standalone Financial Results for the quarter and year ended March 31, 2024 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. 2. Approval of statement of Assets and liabilities for the year ended March 31, 2024. 3. Also note that M/s.Bahedia & Associates, Statutory auditors of the Company have issued the Audit report for the financial year ended on March 31, 2024 with unmodified opinion pursuant to regulation 33(3)(d) of the SEBI(LODR), Regulations, 2015.
22 May 2024
NORRIS MEDICINES LTD. - 524414 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended March 31 2024
NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 ,inter alia, to consider and approve 1. To approve the Standalone Audited Financial Results as per IND-AS along with Audited Report for the quarter and year ended on 31st March, 2024. 2. To approve the Statement of Assets and Liabilities for the year ended March 31, 2024. 3. Any other business with the permission of chair.
08 Apr 2024
NORRIS MEDICINES LTD. - 524414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attachment.
